Hansas immunomodulatory enzyme does the job
Sweden’s Hansa Medical AB presented data showing its experimental drug allowed doctors to perform successful kidney transplants in patients with a particularly high risk of organ rejection.
J&J intensifies vaccine endeavour with Bavarian Nordic
Johnson & Johnson has entered a new deal with Danish biotech Bavarian Nordic worth up to US$879m to develop vaccine regimens against hepatitis B and HIV.
GSK cancels 30 preclinical and clinical programmes
UKs biggest pharma firm announced it will save an additional £1bn each year by 2020. 80% of the pharmaceutical R&D pipeline expenses will be directed towards two current (Respiratory and HIV/infectious diseases) and two potential (Oncology and Immuno-inflammation) priority areas.
Ablynx adds Sanofi to its list of pharma partners
Belgian nanobody-developer Ablynx NV now also works together with French pharma company Sanofi. The deal is potentially worth 2.4bn but comes with an upfront payment of just 23m. The partners will initially focus on therapeutics for the treatment of various immune-mediated inflammatory diseases.
Seventure debuts in Japan with microbiome investment
Venture capitalist Seventure Partners announced that it has participated in a US$13m financing of Japanese biotech company Anaeropharma Science. The investment is made from Seventures Health for Life Capital investment vehicle.